Deutsche Bank
AVLN icon

Deutsche Bank’s Avalyn Pharma AVLN Stock Holding History

Deutsche Bank’s Portfolio AVLN Stock Details AVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$456K Sell
16,016
-917
-5% -$29.6K ﹤0.01% 2687
2026
Q2 		$557K Buy
+16,933
New +$489K ﹤0.01% 2709

Other funds holding AVLN

Andera Partners
Andera Partners Paris $176M AUM 1.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Lewis Asset Management
Lewis Asset Management Lafayette, California $294M AUM 25.62% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Manchester Capital Management
Manchester Capital Management Manchester, Vermont $736M AUM 20.83% 1-Year Est. Return

Deutsche Bank's AVLN Position: Q3 2026 in Review

Deutsche Bank reduced its Avalyn Pharma (AVLN) stake by 5.4% in Q3 2026, selling an estimated $29.6K and leaving 16,016 shares worth $456K. The position accounts for ﹤0.01% of the portfolio, ranked #2687.

Deutsche Bank first reported a position in AVLN in Q2 2026 and has held it in 2 quarters since. The position peaked at $557K in Q2 2026. 23 funds tracked by Wall St. Rank hold AVLN as of Q3 2026.

  • Deutsche Bank held 16,016 shares of Avalyn Pharma worth $456K as of Q3 2026.
  • Deutsche Bank sold 917 Avalyn Pharma shares in Q3 2026, an estimated $29.6K.
  • Avalyn Pharma made up ﹤0.01% of Deutsche Bank's portfolio in Q3 2026, its #2687 holding.
  • Deutsche Bank first reported a position in Avalyn Pharma in Q2 2026 and has held it in 2 quarters since.
  • Deutsche Bank's Avalyn Pharma position peaked at $557K in Q2 2026.
  • 23 funds tracked by Wall St. Rank held Avalyn Pharma as of Q3 2026.

Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.